Mystic Miss Not Make Or Break For Imfinzi
While the failure of AstraZeneca's Imfinzi in the MYSTIC trial for stage IV lung cancer is a blow, it is not going to have much of an effect on the potential for the company which has carved out a sizeable niche for the drug in stage III NSCLC.
You may also be interested in...
Another day and another fail for AstraZeneca's combination of Imfinzi and tremelimumab, this time for extensive-stage small-cell lung cancer.
Imfinzi and tremelimumab plus chemotherapy improved PFS in first-line NSCLC, but overall survival is continuing to be assessed, and AstraZeneca did not clarify how the triple combination compared to Imfinzi alone with chemotherapy.
Prospects for AstraZeneca’s PD-L1 inhibitor Imfinzi received a welcome boost from an interim analysis of the Phase III study in first-line small-cell lung cancer.